Combination therapy of acute myeloid leukemia and myelodysplastic syndrome III.

摘要

The present invention relates to a combination of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof with Quizartinib or a pharmaceutically acceptable salt thereof for treating a patient suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Or a pharmaceutically acceptable salt thereof or a hydrate thereof.